

**Recurrent AUD diagnosis in patients with obesity and a prior history of AUD
during 12-month follow-up time period
(comparison between propensity-score matched cohorts)**

Population	semaglutide cohort	naltrexone/topiramate cohort		HR (95% CI)
Overall (n = 715/cohort)	21.5% (154)	59.9% (428)		0.25 (0.21–0.30)
Women (n = 291/cohort)	17.5% (51)	54.0% (157)		0.23 (0.17–0.32)
Men (n = 379/cohort)	24.0% (91)	66.2% (251)		0.23 (0.18–0.30)
age <= 55 years (n = 423/cohort)	23.9% (101)	62.6% (265)		0.26 (0.21–0.33)
age > 55 years (n = 260/cohort)	23.1% (60)	53.4% (144)		0.32 (0.23–0.43)
Black (n = 76/cohort)	23.7% (18)	51.3% (39)		0.38 (0.22–0.67)
White (n = 444/cohort)	20.9% (93)	58.6% (260)		0.25 (0.20–0.32)
No T2D (n = 282/cohort)	20.2% (57)	57.4% (162)		0.25 (0.19–0.34)
T2D (n = 134/cohort)	25.4% (34)	61.9% (83)		0.27 (0.18–0.41)

0.10 0.20 0.40 0.80 2.0 4.0 8.00
 Hazard Ratio (HR)